Pharmathen S.A., a leading pharmaceutical company headquartered in Greece (GR), has established itself as a key player in the global healthcare industry since its founding in 1975. With a strong presence in Europe, the Middle East, and Africa, Pharmathen focuses on the development, manufacturing, and marketing of innovative generic and specialty pharmaceuticals. The company is renowned for its advanced drug delivery systems and high-quality formulations, which cater to a diverse range of therapeutic areas. Notable achievements include significant investments in research and development, positioning Pharmathen as a trusted partner for both healthcare professionals and patients. With a commitment to excellence and a robust portfolio of products, Pharmathen continues to enhance its market position and contribute to the advancement of global health.
How does Pharmathen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharmathen's score of 34 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Pharmathen reported total greenhouse gas (GHG) emissions of approximately 14,911,000 kg CO2e, comprising about 9,300,000 kg CO2e from Scope 1 and about 5,611,000 kg CO2e from Scope 2 emissions. This represents a 9% reduction in total GHG emissions compared to the base year of 2022, attributed to an increased reliance on renewable energy sources. Pharmathen has set ambitious climate commitments, targeting a 45% reduction in GHG emissions by 2030 for both Scope 1 and Scope 2 emissions. Furthermore, the company has formalised a pledge to achieve net-zero emissions by 2050, focusing on enhancing energy efficiency and increasing the share of renewable energy in its operations. These initiatives reflect Pharmathen's commitment to sustainability and its proactive approach to addressing climate change.
Access structured emissions data, company-specific emission factors, and source documents
2022 | 2023 | |
---|---|---|
Scope 1 | 13,736,000 | 0,000,000 |
Scope 2 | 8,125,000 | 0,000,000 |
Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmathen is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.